Catch-22: Biotech Boom Brings Clinical Services, Regulatory Crunch In China
CDMO, Regulators Play Catch-Up
China’s booming biotech sector shows no signs of slowing and is spurring many contract clinical and manufacturing service providers to double their bets in a market that remains largely untapped for innovative biologics. But whether the boom will turn to a bubble remains to be seen.
You may also be interested in...
As China's regulators renew moves to encourage the development of pediatric medicines, indication expansion may give health players a new growth engine, despite remaining policy challenges and lingering market uncertainties.
The latest development over the licensing arrangement for the anticancer drug may deal a further blow to BeiGene’s oncology commercial efforts in China.
Already priced domestically at a deep discount to counterpart PD-1s in the US, Beigene's tislelizumab could potentially get the first global approval for a China-originated drug in this class, as the immuno-oncology sector as a whole continues to come under pressure in China.